
FDA approves phase 1/2 clinical trial with ABX196 in patients with liver cancer ABX196 to be tested in combination with checkpoint inhibitor nivolumab to treat hepatocellular carcinoma
May 14, 2019
LA JOLLA, CA The U.S. Food and Drug Administration has approved an investigational new drug (IND) application for a phase 1/2 clinical trial of ABX196, a liver cancer therapy developed in the laboratory of Scripps Research Professor Luc Teyton, MD, PhD, and licensed to French pharmaceutical company Abivax.
The FDA approval allows Abivax testing of ABX196 in patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. ABX196 showed potent efficacy against HCC in preclinical testing.
The translation of basic research discoveries to the clinic is the greatest achievement we can hope for as clinician scientists. says Teyton, who is also a member of Abivax's Scientific Advisory Board. The use of ABX196 in the context of immunotherapy has been shown to be beneficial in multiple animal models of cancer, but the results with hepatocellular carcinoma are spectacular. We are looking forward to impacting the disease in patients, especially given the limitations of current therapies.
The open IND allows Abivax to test ABX196 in combination with nivolumab (Opdivo, Bristol-Myers Squibb), a checkpoint inhibitor, in a first phase 1/2 clinical trial to treat patients with HCC. The initial dose-escalation phase of the study will be conducted at the Scripps MD Anderson Cancer Center in San Diego, California, USA; additional leading cancer centers in the U.S. will be involved in the subsequent expansion phase of the study. The first patient is expected to be enrolled this summer.
We are thrilled to have been given the green light by FDA for our U.S. study. says Hartmut J. Ehrlich, MD, chief executive officer of Abivax. This open IND allows Abivax, in collaboration with leading key opinion leaders at internationally renowned U.S. cancer centers of excellence, to explore the clinical potential of our iNKT agonist ABX196 to broaden and potentiate the activity of the checkpoint inhibitor nivolumab. Based on its unique mechanism of action and exciting preclinical data in several cancer models, we believe ABX196 is a promising immunotherapeutic product candidate for patients with liver cancer that may also have potential in other cancers.
ABX196 is a synthetic glycolipid agonist of invariant natural killer T cells (iNKT) in a liposomal formulation. A phase 1 clinical trial conducted by Abivax in healthy volunteers has been completed and demonstrated safety and tolerability as well as a potent activation of iNKT cells. ABX196, both alone and in combination with a checkpoint inhibitor, showed a statistically highly significant therapeutic effect in reducing tumor growth as measured by MRI and increasing survival in mice with HCC. Abivax holds exclusive rights to ABX196 from Scripps Research, the University of Chicago, and Brigham Young University.
Despite the recent introduction of checkpoint inhibitors, hepatocellular carcinoma continues to be a substantial therapeutic challenge, as only about 20 percent of the treated patients show a response to these new drugs says Darren Sigal, MD, program director of GI Oncology at Scripps Clinic and Scripps MD Anderson Cancer Center in San Diego, and principal investigator of the study. While checkpoint inhibitors block a do not attack me' signal on cancer cells, ABX196 activates iNKT cells, a subpopulation of lymphocytes that is critical for mounting an effective immune response. The synergy between these two molecules carries substantial promise for improved outcomes for patients with this deadly cancer.
Checkpoint inhibitors like nivolumab are a leading class of therapeutic monoclonal antibodies that block certain endogenous proteins (PD-1/PDL-1) made by immune cells, such as T cells, as well as some cancer cells. These proteins effectively hijack the immune system, causing it to keep immune responses in check and preventing T cells from killing cancer cells. When these proteins are blocked, the brakes on the immune system are released and T cells are able to kill cancer cells much more efficiently. In some cancers, treatment with checkpoint inhibitors has been highly efficacious. However, due to the tumor micro-environment in other cancers, such as HCC, checkpoint inhibitors can have difficulties exerting their effects. ABX196 is intended as a drug that will potentiate the efficacy of checkpoint inhibitors by activating iNKT cells to kill tumor cells.
HCC is the most common form (75 to 90 percent) of primary liver cancer in adults. It typically occurs in the setting of chronic liver inflammation and/or cirrhosis and is closely linked to chronic viral infection such as hepatitis B or C, exposure to toxins such as alcohol, and to certain diseases such as non-alcoholic steatohepatitis (NASH).
The incidence of and deaths related to HCC are increasing in the United States and globally due to hepatitis B and C virus infections, as well as NASH. Prevalence data from 2018 show a total of 79,000 cases of HCC in the U.S. and G5 Europe (Germany, France, Italy, Spain and the UK), with 67,000 new cases, and a total of 260,000 cases in China with 338,000 new cases. Globally, there were 841,000 new cases of liver cancer (ranking it sixth of all reported cancers) and 782,000 fatalities (ranking it fourth) in 2018.
Currently, the American Cancer Society reports five-year survival rates in the U.S. of 31 percent for localized HCC, 11 percent for regional, and 2 percent for distant or metastatic, indicating a clear unmet medical need for improved therapies for HCC.
Cancer Immunology & Microbiology Teyton, Luc
Most recent headlines
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
01/06/2026
January 6 2026, 05:30 (PST) Dolby Sets the New Standard for Premium Entertainment at CES 2026
Throughout the week, Dolby brings to life the latest innovatio...
02/05/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
01/05/2026
January 5 2026, 18:30 (PST) NBCUniversal's Peacock to Be First Streamer to ...
07/04/2026
Ikegami USA will launch a refinement to the UHK-X700 and UHK-X750 3-CMOS -in. UHD cameras in the UNICAM XE series plus two new 7-in. viewfinders at NAB 2026 in...
07/04/2026
The NAB Leadership Foundation and NAB PILOT will host a career mixer for technology students at NAB Show 2026 on April 18, 5-6:30 p.m., North Hall, Room N225/22...
07/04/2026
Audinate Group Limited and Futuresource Consulting have published results from a...
07/04/2026
Eluvio has announced the commercial availability of its Content Fabric Bucharest...
07/04/2026
Eluvio has unveiled a new architecture for video AI and an updated Eluvio Video Intelligence Editor (EVIE) ahead of NAB Show 2026. Eluvio AI runs analysis and i...
07/04/2026
The Professional Fighters League (PFL) has announced a deal with Sky New Zealand...
07/04/2026
The NBA and Enjoy Basketball, the digital media company co-founded by YouTube cr...
07/04/2026
The 4,000-sq.-ft. space in Frisco, TX, has produced live and packaged programmin...
07/04/2026
What began as a referee training tool is evolving into a powerful production ass...
07/04/2026
Manifold Technologies will announce at NAB Show 2026 (Booth C.1808) that its manifold CLOUD platform will be available as a deployable application within NEP Pl...
07/04/2026
Shaquille O'Neal, Authentic Brands Group, and TNT Sports, in partnership wit...
07/04/2026
Telos Alliance will debut the Omnia XII, a new FM/HD/DAB audio processor, at NAB Show 2026 in Las Vegas.
Built on a 2RU hardware platform, Omnia XII features a...
07/04/2026
Amazon Web Services (AWS) will exhibit at NAB Show 2026 (April 18-22, Las Vegas Convention Center, Booth W1701), with demonstrations, speaking sessions, and int...
07/04/2026
Synamedia will demonstrate AI by Quortex at NAB Show 2026, a framework that applies AI capabilities to video workflows on demand rather than continuously. The s...
07/04/2026
TVNewsCheck will present its 15th annual Women in Technology Awards on Tuesday, April 21, at 5 p.m. PT at NAB Show, in the Media and Entertainment Theater (W146...
07/04/2026
Akta will demonstrate its AI video platform at NAB Show 2026, highlighting new capabilities in media processing and vertical video formatting alongside its exis...
07/04/2026
ESPN and Disney have announced the launch of ESPN on Disney in Europe and select Asia-Pacific markets, bringing the offering to 53 countries and territories a...
07/04/2026
LOS ANGELES, CA, April 7, 2026 - The nonprofit Sundance Institute announced today the fellows selected for the 2026 Native Lab, the signature initiative of the ...
07/04/2026
Starting today, Prompted Playlist is expanding beyond music to now include podca...
07/04/2026
Launched alongside piano promotion
The latest instalment in VSL's Synchron Series line-up captures the sound of a faithful copy of a Fran ois tienne Bl...
07/04/2026
Flagship sampling pad gets an update
Roland's flagship sampling pad has just received a major update that kits it out with an array of new features and ...
07/04/2026
Popular compact wireless system upgraded
Sound Devices have recently introduced a new and improved version of their compact wireless transmitter bodypacks, ...
07/04/2026
The November 2025 YEP Newsletter highlights a recent YEP Coffee Chat, offering members the chance to connect with industry professionals in an informal setting ...
07/04/2026
The December 2025 YEP Newsletter includes a Spotlight on Emily Vail, showcasing her career journey and work in the industry, alongside Mentorship Reflections by...
07/04/2026
Ground-Based Electro-Optical Deep Space Surveillance (GEODSS) telescope operated...
07/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
07/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
07/04/2026
Catgut Sound Owner and Production Sound Mixer Chris Welcker, CAS, has built a career at the intersection of music and film. A former musician and composer, Welc...
07/04/2026
SDVI Corporation today announced the next generation of its Rally media supply chain management platform, introducing a redesigned orchestration engine that rep...
07/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
07/04/2026
Frequency, the engine behind many of the world's leading streaming television channels, at NAB 2026 will be launching new Studio services to help content ow...
07/04/2026
Ikegami USA has chosen NAB 2026 in Las Vegas as the launch platform for new additions to its range of broadcast-quality television production equipment. These w...
07/04/2026
April 19, 2026, Las Vegas Kiloview, an innovative provider of AV-over-IP technologies, will showcase its latest broadcast IP solutions at NAB 2026, presenting...
07/04/2026
Bitmovin has announced support for Server-Guided Ad Insertion (SGAI) across its playback products using HLS interstitials, enabling more advanced ad-supported s...
07/04/2026
Synamedia is unveiling AI by Quortex at The NAB show, a just-in-time AI plugin framework that applies intelligence only when needed across video processing, dis...
07/04/2026
Cuez will showcase four additions to its cloud-based newsroom, rundown and automation platform at NAB Show 2026 (April 18 22, Las Vegas, Booth N1867):
Cuez ...
07/04/2026
CueScript to Showcase Innovations at NAB that Add Mobility Options, Ease Editing...
07/04/2026
Barix Extends Transport Options for Multi-Engine IP Encoder
Brie Clayton April 7, 2026
0 Comments
New for NAB, Barix adds SRT and RIST support to Mult...
07/04/2026
Elite Media Technologies Selects Interra Systems' BATON File-Based QC Soluti...
07/04/2026
Tightrope Media Systems to Debut Cablecast LiveBridge for Simultaneous Streaming...
07/04/2026
Cuez Brings Four New Innovations to NAB 2026: From Story-Centric Newsroom to Ope...
07/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
07/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
07/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
07/04/2026
Share
Copy link
Facebook
X
Linkedin
Bluesky
Email...
07/04/2026
Designed for synchronized multi-stream playback, low-latency delivery, and real-time analytics, MATCH introduces a unified viewing experience for sports broadca...